tag:blogger.com,1999:blog-7857054149675424609.post7349628408614127143..comments2024-02-24T08:58:08.581+00:00Comments on RNAi Therapeutics: ISIS Files Aggressive Lawsuit against SantarisDirk Hausseckerhttp://www.blogger.com/profile/18320439857875629714noreply@blogger.comBlogger8125tag:blogger.com,1999:blog-7857054149675424609.post-89299656779721284382011-09-26T00:55:45.582+00:002011-09-26T00:55:45.582+00:00As it pertains to future competition between these...As it pertains to future competition between these two companies for commercialization partners, future development of 3'-Fluoro Hexitol Nucleic Acid (FHNA) Modified Oligonucleotide chemistries, recently described in the article in press from Egli et al. (which includes Isis & Regulus co-authors), will be interesting to follow. <br /><br />In single dose and 3 week dosing schedules with Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-4590124600358841952011-09-24T15:30:46.601+00:002011-09-24T15:30:46.601+00:00If Santaris' LNA antisense was so toxic as ISI...If Santaris' LNA antisense was so toxic as ISIS claims, why is ISIS so concerned about competition from Santaris? It's also not like it has just emerged that Santaris has these LNA-antisense partnerships. Seems like 4-5 years late to sue them now.Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-60286011143881562011-09-24T05:30:35.063+00:002011-09-24T05:30:35.063+00:00My last comment/question on the litigation.
I am ...My last comment/question on the litigation.<br /><br />I am not a lawyer and may be misstating the issue, but it seems because Santaris is obtaining financial gain by licensing technology dependent on the unlicensed intellectual property of others they have moved beyond the scope and spirit of the Research Exemption. Doesn’t ISIS deserve some of the fruits being reaped by Santaris at ISIS’ tettrazininoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-78385575139081152622011-09-24T04:47:41.756+00:002011-09-24T04:47:41.756+00:00If the data in the paper (http://nar.oxfordjournal...If the data in the paper (http://nar.oxfordjournals.org/content/35/2/687.full) is accurate, which I assume you are not questioning, why do you consider it a punch below the belt? Do you feel they are misinterpreting the findings or perhaps displeased that they paid the Open Access publication charges?tettrazininoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-56729731522621931572011-09-24T03:40:28.244+00:002011-09-24T03:40:28.244+00:00Jet...the paper below by ISIS relates to the conte...Jet...the paper below by ISIS relates to the contention that LNAs have tox issues. I thought that paper was a punch below the belt. ISIS has published similar 'comparison papers' to disparage other oligo technologies (e.g. U1-adaptors), so there is a pattern. In any case, you can as easily find similar tox issues with ISIS' antisense compounds. These are also to a certain degree Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-28566613556647762882011-09-24T03:27:57.520+00:002011-09-24T03:27:57.520+00:00You are right: The first question will be whether ...You are right: The first question will be whether the ISIS patents apply to Santaris' chemistries in the first place (and whether Santaris does not have access to them through a license from ISIS). I'm not sure, but ISIS obviously assumes that.<br /><br />What makes this case interesting is the Research Exemption. You would not believe how much RNAi services are being offered and sold.Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-4726759495766063382011-09-24T03:24:00.335+00:002011-09-24T03:24:00.335+00:00I really think that your comments are misplaced an...I really think that your comments are misplaced and several other view points could also apply. It is well known that you are not a fan of ISIS so the most likely negative comment that fits the bill is what is grabbed at. For example, ISIS has had a long-standing program for LNA's and continue to develop that program. Santaris definitely does not have a monopoly on that IP. The toxicity jetmanbashnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-79481014391205694222011-09-23T20:48:29.735+00:002011-09-23T20:48:29.735+00:00Is Santaris licensing patented technology owned by...Is Santaris licensing patented technology owned by a third party seems to be the core issue. If that is the case it would seem to be a rather broad extension of the Research Exemption Doctrine.<br /> <br />Clearly ISIS is putting the industry on notice that even if the Research Exemption Doctrine is applicable, it still precludes others from commercializing ISIS’ intellectual property.<br />On tettrazininoreply@blogger.com